Early Mortality after TIPS in a Liver Transplant Recipient

Very few studies have evaluated transjugular intrahepatic portosystemic shunt (TIPS) insertion in liver transplant recipients. In general, it appears to be a viable long-term treatment option in some patients and may serve as a bridge to retransplantation in others. The overall risk of early mortality appears to be similar to patients without transplants; mortality is more common in patients with advanced liver and kidney disease.

SUGGESTED READINGS

• 1 Ferral H, Gamboa P, Postoak D W et al.. Survival after elective transjugular intrahepatic portosystemic shunt creation: prediction with model for end-stage liver disease score.  Radiology. 2004;  231 231-236
• 2 Harrod-Kim P, Saad W, Waldman D. Predictors of early mortality after transjugular intrahepatic portosystemic shunt creation for the treatment of refractory ascites.  J Vasc Interv Radiol. 2006;  17 1605-1610
• 3 Patel N H, Patel J, Behrens G, Savo A. Transjugular intrahepatic portosystemic shunts in liver transplant recipients: technical considerations and review of the literature.  Semin Intervent Radiol. 2005;  22 329-333
• 4 Ripamonti R, Ferral H, Alonzo M, Patel N H. Transjugular intrahepatic portosystemic shunt-related complications and practical solutions.  Semin Intervent Radiol. 2006;  23 165-176
• 5 Russo M W, Sood A, Jacobson I M, Brown Jr R S. Transjugular intrahepatic portosystemic shunt for refractory ascites: an analysis of the literature on efficacy, morbidity, and mortality.  Am J Gastroenterol. 2003;  98 2521-2527
• 6 Van Ha T G, Funaki B S, Ehrhardt J et al.. Transjugular intrahepatic portosystemic shunt placement in liver transplant recipients: experiences with pediatric and adult patients.  AJR Am J Roentgenol. 2005;  184 920-925